Novo Nordisk acquires Embark Biotech, including its lead asset targeting obesity and other cardiometabolic diseases.

/PRNewswire/ -- Embark Laboratories announced today that Novo Nordisk has acquired Embark Biotech, including its lead metabolic program, and has entered a...

Related Keywords

Copenhagen ,Køavn ,Denmark ,Zach Gerhart Hines ,Jakob Bondo Hansen ,Metabolic Research ,Bioinnovation Institute ,Novo Holdings ,Obesity Research At Novo Nordisk ,Novo Nordisk Foundation Center ,Venture House Program ,Novo Nordisk Foundation ,Innovation Fund Denmark ,Novo Nordisk ,University Of Copenhagen ,Embark Laboratories ,Embark Biotech ,Vice President ,Obesity Research ,Chief Technology Officer ,Innovation Fund ,Basic Metabolic Research ,Associate Professor Zach Gerhart Hines ,Professor Thue ,Venture House ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Stem Science ,Tech ,Engineering ,Death ,Computer Amp Electronics ,Acquisitions ,Ergers And Takeovers ,